Anti-ferritin polyclonal antibody

Drug Profile

Anti-ferritin polyclonal antibody

Alternative Names: Ferritarg P; Ferritarg-P - MABLife

Latest Information Update: 18 Sep 2015

Price : $50

At a glance

  • Originator MAT Biopharma
  • Developer MABLife
  • Class Antineoplastics; Polyclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Iron-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hodgkin's disease

Most Recent Events

  • 18 Sep 2015 No recent reports on development identified - Phase-I/II for Hodgkin's disease in France (IV)
  • 29 Jul 2011 MAT Biopharma has been renamed as MABLife
  • 22 Feb 2011 Ferritarg® is still in phase I/II development for refractory Hodgkin's lymphoma in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top